Highlights for 2018 include the addition of breakpoints for ceftazidime-avibactam and dalbavancin, expansion of the mCIM test for detection of metallo beta-lactamases and new tables and expanded recommendations for QC of beta-lactam combination agents. These changes and several other new recommendations found in the three documents will be discussed. In addition, a composite list of questions and answers raised during the webinar or asked subsequent to the webinar will be distributed to all participants.
After viewing the program, the learner will be able to:
- Identify the major changes found in the updated editions of CLSI documents M100, M02, and M07.
- Design a strategy for implementing the new practice guidelines into laboratory practices.
- Develop a communication strategy for informing clinical staff of significant AST and reporting changes.
Janet Hindler, MCLS, MT(ASCP), F(AAM)
Clinical Microbiologist, Los Angeles, CA
Romney M. Humphries, PhD, D(ABMM)
Chief Scientific Officer, Accelerate Diagnostics, Tucson, AZ
Audrey Schuetz, MD, MPH, FCAP
Associate Professor of Laboratory Medicine and Pathology, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN